Interleukin-1 polymorphisms and graft-vs-host disease

REFERENCES

• Bensinger WI, Storb R Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 2001;5:67–86.
   Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi M-S Storb R, Donnall Thomas E. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69: 204–217.
   Google Scholar
• Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, Vogelsang GB. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001;97:1219–1226.
   Google Scholar
• Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101:3373–3385.
   Google Scholar
• Duell T, van Lint MT, Ljungman P, Tichelli A, Socie G, Apperley JF, Weiss M, Cohen A, Nekolla E, Kolb H-J. Health and functional status of long-term survivors of bone marrow transplantation. Ann Intern Med 1997;126:184–192.
   Google Scholar
• Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964–2968.
   Google Scholar
• Krenger W, Hill GR, Ferrara JLM. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997;64: 553–558.
   Google Scholar
• Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumour necrosis factor alpha during graft-versus-host disease. J Exp Med 1992;175:405–413.
   Google Scholar
• Schlomchik WD, Couzens MS, Tang CB, McNiff JM, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–415.
   Google Scholar
• Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graft-versus-host disease as a model for scleroderma: mast cell depletion with deposition of immunoglobulin in the skin and fibrosis. Cell Immunol 1985;94:73–84.
   Google Scholar
• Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457–499.
   Google Scholar
• Busfield SJ, Comrack CA, Yu G, L,eiby KR, Holmgren LM, Gearing DP, Pan Y. Identification and gene organization of three novel members of the IL-1 family on human chromo-some 2. Genomics 2000;66: 213–216.
   Google Scholar
• Kumar S, McDonnell PC, Lehr R, Caper EA, Tal-Singer R, Wells GI, Doyle ML, Young PR. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000;275: 10308–10314.
   Google Scholar
• Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754–2759.
   Google Scholar
• Hill GR, Teskima T, Gerbitz A, Crawford JM, Ferrara JLM. Differential roles of IL-1 and TNF-a on graft-versus-host disease and graft versus leukaemia. J Chin Invest 1999;104: 459–467.
   Google Scholar
• Cooke KR, Gerbitz A, Crawford JM, Rossignol DP, Ferrara JLM. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Chin Invest 2001;107:1581–1589.
   Google Scholar
• Teshima T, Ordemann R, Reddy P, Ferrara JLM. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575–581.
   Google Scholar
• Antin J, Weinstein H, Guinan E, Parsons SK, Ballen KK, Rimm IJ, Falzarano G. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84: 1342–1348.
   Google Scholar
• Antin J, Weisdorf H, Neuberg D, Alyea E, McGarigle C, Soiffer R, Ferrara JLM. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a rando-mized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplanta-tion. Blood 2002;100: 3479–3482.
   Google Scholar
• Holler E, Kolb HJ, Mittermuller J, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumour necrosis factor a (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 1995;86: 890–899.
   Google Scholar
• Cullup H, Wang XN, Sviland L, Dickinson AM. Neutralisa-tion of IL-1 receptor antagonist is associated with increased IL-1 mediated damage in a human in vitro model of GVHD. Bone Marrow Transplant 2004;33:S79.
   Google Scholar
• Hammerberg C, Arend WP, Fisher GJ Voorhees JJ, Cooper KD. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992;90:571–583.
   Google Scholar
• Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breath-nach SM, Brennan FM. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin a in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992;127: 305–311.
   Google Scholar
• Bidwell JL, Keen LJ, Gallagher G, Oksenberg J, McNicholl J, Poicot F, Hardt C, D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1:3–19.
   Google Scholar
• Dickinson AM, Cavet J, Cullup H, Wang X-N, Sviland L, Middleton PG. GvHD risk assessment in hematopoietic stem cell transplantation: role of cytokine gene polymorphisms and an in vitro human skin explant model. Hum Immunol 2001;62:1266–1276.
   Google Scholar
• Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL- lbeta genes. Eur J Immunol 1998;28:2598–2602.
   Google Scholar
• Bailly S, Israel N, Fay M, Gougerot-Pocidalo MA, Duff GW. An intronic polymorphic repeat sequence modulates inter-leukin-1 alpha gene regulation. Mol Immunol 1996;33: 999–1006.
   Google Scholar
• Bailly S, Fay M, Israel N, Gougerot-Pocidalo MA. The transcription factor AP-1 binds to the human interleukin 1 alpha promoter. Eur Cytokine Netw 1996;7: 125–128.
   Google Scholar
• Lin M-T, Martin PJ, Tseng L-H, Petersdorf EW, Hansen JA. Correlation between polymorphisms of the IL-1 gene complex and development of acute graft-versus-host disease after hematopoietic cell transplantation. Blood 2000;96:396a.
   Google Scholar
• Cullup H, Dickinson AM, Cavet J, Jackson G, Taylor PRA, Middleton PG. Donor interleukin-1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic trans-plants. Br J Haematol 2001;113:807–813.
   Google Scholar
• Rocha V, Franco RF, Porcher R, Devegie A, Esperou H, Ribaud P, Zago MA, Gluckman E. Host defense and inflammatory gene polymorphisms are associated with out-comes after HLA-identical sibling bone marrow transplantation. Blood 2002;100:3908–3918.
   Google Scholar
• Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of IL-la constitute independent risk factors for chronic graft versus host disease following allogeneic bone marrow transplantation. Br J Haematol 2003;122:778–787.
   Google Scholar
• MacMillan ML, Radloff GA, DeFor TE, Weisdorf DJ, Davies SM. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 2003;121: 597–604.
   Google Scholar
• Mullighan C, Headey S, Doherty K, Schwarer A, Szer J, Tait BD, To B, Bardy P. Non-HLA immunogenetic polymorph-isms and the risk of complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004;27:587–596.
   Google Scholar
• El-Omar EM. The importance of interleukin-lfi in Helicobac-ter pylori associated disease. Gut 2001;48:743–747.
   Google Scholar
• Smith AJP, Keen LJ, Billingham MJ, Sims JE, Doherty M, Spector TD, Bidwell JL. Extended haplotypes and linkage disequilibrium in the IL-1R1 - IL-1A - IL-1B - IL-1RN gene cluster: association with knee osteoarthritis. Genes Immun 2004;5: 451–460.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Rimm AA, Ringden 0, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–562.
   Google Scholar
• Giralt S, Estey E, Albitar M, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson BS, Beran M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukaemia without myeloablative therapy. Blood 1997;89:4531–4536.
   Google Scholar
• Slavin S, Nagler A, Naparstek E, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal 0 et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–763.
   Google Scholar
• Valks R, Fernandez-Herrera J, Bartolome B, Fraga J, Dauden E, Gracia-Diez A. Late appearance of acute graft-versus-host disease after suspending immunosuppressive drugs. Arch Dermatol 2001;137:61–65.
   Google Scholar
• Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortim MN. Consensus among bone marrow transplanters for diagnosis grading and treatment of chronic GvH disease. Committee of the International Bone Marrow Registry. Bone Marrow Transplant 1989:4:247–254.
   Google Scholar
• Jacobsohn DA, Montross S, Anders V, Vogelsang GB. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant 2001;28:1047–1051.
   Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, Mans B, Storb R. Graft-versus-host disease after non-myeloablative versus con-ventional hematopoietic stem cell transplantation. Blood 2003;102:756–762.
   Google Scholar